Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Agenus, Inc. (AGEN)

Core Points - A securities class action lawsuit has been filed against Agenus Inc. for alleged misleading statements regarding its combination therapy of botensilimab and balstilimab [1][2] - The lawsuit claims that the effectiveness of the therapy was overstated, leading to a significant drop in stock price following negative FDA feedback [2] Group 1 - The lawsuit was filed on behalf of all individuals or entities who purchased Agenus securities between January 23, 2023, and July 17, 2024 [1] - The complaint alleges that the combination therapy was less effective than previously communicated to investors [2] - Following the announcement of the FDA's advice against submission for Accelerated Approval, Agenus' stock price fell nearly 59% [2] Group 2 - Investors are encouraged to contact the law firm before the lead plaintiff motion deadline of November 5, 2024 [3] - The lead plaintiff will represent the interests of other class members in the litigation [3] - Contact information for the law firm is provided for those interested in discussing their rights or interests regarding the class action [3]